Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina Inc (NASDAQ: ILMN) and privately-held Kartos Therapeutics have announced a partnership to develop a next-generation sequencing-based TP53 companion diagnostic. The diagnostic will be based on Illumina's pan-cancer comprehensive genomic profiling assay, TruSight Oncology 500 (TSO 500), and will be used to detect TP53 mutations in multiple hematologic indications.

Illumina, Kartos Therapeutics Team Up To Develop Companion Diagnostic For TP53-Haboring Cancer Indications

SAN DIEGO--(BUSINESS WIRE)--Illumina and Kartos Therapeutics announce a new partnership to co-develop a TP53 CDx based on the TruSight™ Oncology 500 (TSO 500) assay.

Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic

Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.

Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?

SAN DIEGO--(BUSINESS WIRE)--Illumina disagrees with the European Commission's Directorate-General for Competition's decision to review Illumina's acquisition of GRAIL.

Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Sometimes the most carefully laid plans hit unforeseen snags.

Is Illumina Still a Buy Without the GRAIL Acquisition?

The gene sequencing giant has a couple of key challenges going forward.

The Big Questions for Illumina After Its Q1 Sneak Peek and 2021 Guidance

SINGAPORE--(BUSINESS WIRE)--Illumina Named One of Singapore's Best Employers

CORRECTING and REPLACING Illumina Named One of Singapore's Best Employers

Illumina Named One of Singapore's Best Employers

AbbVie

ACADIA Pharma

Alexion Pharma

AstraZeneca

Biogen

BioNTech SE

CRISPR Therapeutics

Editas Medicine

Kadmon Hlds

Moderna

Pfizer

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

This giant of the genomic revolution ticks nearly all the boxes dividend investors should look for.

This Unstoppable Stock Doesn't Pay a Dividend Yet, but It Could

The chances are certainly higher now that the deal won't happen.

Could Illumina's Quest to Acquire GRAIL Fail?

The chief executive of life sciences company Illumina argued Thursday his company's deal to buy back GRAIL would lead to cheaper cancer tests rather than potentially pushing up prices as the government alleged in seeking to block the $7.1 billion transaction.

Illumina CEO says GRAIL deal is good for competition

The biotech was under pressure last month, but it's bouncing back in April.

Why Illumina Stock Fell 12.6% in March

The DNA sequencing company is gearing up to report a big beat later this month.

Why Illumina Stock Just Jumped 10%

Illumina's (ILMN) revenue improvement in the first quarter is likely to have been boosted by on-going business recovery.

Illumina (ILMN) Preliminary Q1 Revenues Rebound, '21 View Up

Illumina stock gapped up Tuesday after the company preannounced 26% revenue growth in the first quarter and boosted its full-year guidance. Analysts were split on the preannouncement.

Illumina Stock Pops As Covid Surveillance Helps Drive Unexpected Beat And Raise

The shares of Illumina Inc (NASDAQ:ILMN) are surging today, up 9.2% to trade at $420 at last check, after the company announced better-than-expected preliminary current-quarter and full-year guidance.

ILMN Jumps Higher on Upbeat Guidance

The stock price of Illumina, Inc. (NASDAQ: ILMN) increased by over 9% pre-market. This is why it happened.

Illumina Stock Price Increased Over 9% Pre-Market: Why It Happened

Shares of Illumina Inc. jumped more than 13% in the extended session Monday after the biotech company said it expects first-quarter revenue to top $1 billion thanks to "record" orders and revenue growth in its gene-sequencing and related businesses. Illumina said it expects first-quarter revenue of about $1.085 billion, which would compare with revenue of $859 million in the first quarter of 2020.

Illumina stock rallies 13% after biotech says it expects Q1 sales to top $1 billion

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2021 and updated its fiscal year 2021 revenue guidance. Subject to quarter-end closing adjustments, Illumina expects to report first quarter 2021 revenue of approximately $1,085 million, compared to $859 million in the first quarter of 2020. This represents year-over-year revenue growth of approximately 26% for the quarter. For fiscal year 2021, Illumina now expects

Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021

The company's attempts to grow through acquisition keep running into problems.

Is Illumina Still a Good Stock to Buy?

Illumina (ILMN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Illumina (ILMN) Moves 4.1% Higher: Will This Strength Last?

BlackBerry

PLBY Group

Analysts at Canaccord Genuity came out Wednesday morning with two rating upgrades, along with initiating coverage with a Buy rating on a third company.

Canaccord Genuity Ups Ratings on Playboy, BlackBerry, Illumina

According to FTC, the Illumina (ILMN) and Grail merger will diminish the scope of innovation in the U.S. market for MCED tests.

Illumina's (ILMN) Grail Merger in Trouble as FTC Files Suit

The Federal Trade Commission (FTC) is reportedly looking to stop Illumina Inc's (NASDAQ: ILMN) $7.1 billion proposed acquisition of Grail Inc. FTC believes that the deal would slow innovation in cancer tests. Illumina was the only U.S. company to provide DNA sequencing for multi-cancer early detection tests, the FTC said.

News for Illumina Stock (ILMN)